Asensus Surgical Announces Klinikum Idar-Oberstein Hospital in Germany to Initiate Senhance Surgery Program
06 November 2023 - 12:55PM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient, announced that Klinikum Idar-Oberstein Hospital
located in Germany, has entered into a lease agreement to utilize a
Senhance® Surgical System.
"We are pleased to collaborate with Klinikum Idar-Oberstein
Hospital as they aim to enhance patient outcomes through advanced
minimally invasive surgery. The innovative features of the Senhance
System, combined with the established laparoscopic approach, will
bring valuable enhancements to the Idar-Oberstein Hospital,"
commented Anthony Fernando, President and CEO of Asensus Surgical.
"We look forward to working with Dr. Christos Zigouris and team to
ensure the success of their team’s Senhance program."
“With the introduction of the Senhance program at Idar-Oberstein
Hospital, we are raising the bar for patient care,” said Dr. med.
Christos Zigouris, Chief Physician Clinic for General, Visceral and
Minimally Invasive Surgery. “The incorporation of the Senhance
System represents a significant leap forward for our hospital. Its
advanced clinical intelligence, combined with a comprehensive suite
of minimally invasive instruments, promises to yield improved and
more predictable patient outcomes.”
Caption: The Senhance Surgical System is
designed to increase surgeon control and reduce variability through
Augmented Intelligence and deep learning capabilities.
About Klinikum Idar-Oberstein Hospital
The Idar-Oberstein Hospital is a respected healthcare
institution and affiliated with the Johannes Gutenberg University
Mainz. As an academic teaching hospital, it accommodates 527 beds
and 35 day clinic places, housing 17 specialist departments and two
institutes. With a commitment to quality care, the hospital has
been a trusted presence in the community. Its emphasis on patient
well-being ensures that healthcare is provided with compassion and
tailored to individual needs.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundations of Digital Laparoscopy and the Senhance
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit™ to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, and select other countries. For a complete
list of indications for use, visit: www.senhance.com/indications.
To learn more about Performance-Guided Surgery, and digital
laparoscopy with the Senhance Surgical System visit
www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/@AsensusSurgical
Vimeo: https://vimeo.com/asxc
TikTok: https://www.tiktok.com/@asensus_surgical
Forward-Looking Statements
This press release includes statements relating to the Senhance
Surgical System and Klinikum Idar-Oberstein Hospital in
Idar-Oberstein, Germany initiating a program with the Senhance
System. These statements and other statements regarding our future
plans and goals constitute "forward looking statements" within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, and are intended to
qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to risks and uncertainties that are often difficult to
predict, are beyond our control and which may cause results to
differ materially from expectations and include whether the
innovating features of the Senhance System, combined with the
established laparoscopic approval will bring valuable enhancements
to Klinikum Idar-Oberstein Hospital and whether the Senhance
Surgical System will yield improved and more predictable outcomes
for Klinikum Idar-Oberstein Hospital patients. For a discussion of
the risks and uncertainties associated with the Company’s business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2022, filed with the SEC on March 2, 2023
and our other filings we make with the SEC. You are cautioned not
to place undue reliance on these forward looking statements, which
are based on our expectations as of the date of this press release
and speak only as of the origination date of this press release. We
undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Dan Ventresca
Matter Communications
AsensusPR@matternow.com
617-874-5488
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/a756a7ba-b3b7-464a-a7ea-6bdbbf9b899a
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
Von Mai 2023 bis Mai 2024